Your browser doesn't support javascript.
loading
MHC associations with clinical and autoantibody manifestations in European SLE.
Morris, D L; Fernando, M M A; Taylor, K E; Chung, S A; Nititham, J; Alarcón-Riquelme, M E; Barcellos, L F; Behrens, T W; Cotsapas, C; Gaffney, P M; Graham, R R; Pons-Estel, B A; Gregersen, P K; Harley, J B; Hauser, S L; Hom, G; Langefeld, C D; Noble, J A; Rioux, J D; Seldin, M F; Vyse, T J; Criswell, L A.
Afiliação
  • Morris DL; Department of Medical & Molecular Genetics, King's College London School of Medicine, Guy's Hospital, London, UK.
  • Fernando MM; Department of Medical & Molecular Genetics, King's College London School of Medicine, Guy's Hospital, London, UK.
  • Taylor KE; Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Chung SA; Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Nititham J; Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Alarcón-Riquelme ME; 1] Department of Human DNA Variability, GENYO, Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía, Granada, Spain [2] Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma, OK, USA.
  • Barcellos LF; Genetic Epidemiology and Genomics Laboratory, Division of Epidemiology, School of Public Health, University of California, Berkeley, CA, USA.
  • Behrens TW; Immunology Biomarkers Group, Genentech, South San Francisco, CA, USA.
  • Cotsapas C; Department of Neurology, Yale School of Medicine, Connecticut, CT, USA.
  • Gaffney PM; Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma, OK, USA.
  • Graham RR; Immunology Biomarkers Group, Genentech, South San Francisco, CA, USA.
  • Pons-Estel BA; Rheumatology Service, Hospital Provincial de Rosario, Sanatorio Parque, Rosario, Argentina.
  • Gregersen PK; The Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, North Shore LIJ Health System, Manhasset, NY, USA.
  • Harley JB; Cincinnati Children's Hospital Medical Center and US Department of Veterans Affairs Medical Center, Cincinnati, OH, USA.
  • Hauser SL; Department of Neurology, University of California San Francisco, San Francisco, CA, USA.
  • Hom G; Immunology Biomarkers Group, Genentech, South San Francisco, CA, USA.
  • Langefeld CD; Department of Biostatistical Sciences, Wake Forest University Health Sciences, Wake Forest, NC, USA.
  • Noble JA; Children's Hospital Oakland Research Institute, Oakland, CA, USA.
  • Rioux JD; Department of Medicine, Université de Montréal and Research Center, Montreal Heart Institute, Montreal, QC, Canada.
  • Seldin MF; University of California Davis, Davis, CA, USA.
  • Vyse TJ; Department of Medical & Molecular Genetics, King's College London School of Medicine, Guy's Hospital, London, UK.
  • Criswell LA; Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Genes Immun ; 15(4): 210-7, 2014 Apr.
Article em En | MEDLINE | ID: mdl-24598797
ABSTRACT
Systemic lupus erythematosus (SLE) is a clinically heterogeneous disease affecting multiple organ systems and characterized by autoantibody formation to nuclear components. Although genetic variation within the major histocompatibility complex (MHC) is associated with SLE, its role in the development of clinical manifestations and autoantibody production is not well defined. We conducted a meta-analysis of four independent European SLE case collections for associations between SLE sub-phenotypes and MHC single-nucleotide polymorphism genotypes, human leukocyte antigen (HLA) alleles and variant HLA amino acids. Of the 11 American College of Rheumatology criteria and 7 autoantibody sub-phenotypes examined, anti-Ro/SSA and anti-La/SSB antibody subsets exhibited the highest number and most statistically significant associations. HLA-DRB1*0301 was significantly associated with both sub-phenotypes. We found evidence of associations independent of MHC class II variants in the anti-Ro subset alone. Conditional analyses showed that anti-Ro and anti-La subsets are independently associated with HLA-DRB1*0301, and that the HLA-DRB1*0301 association with SLE is largely but not completely driven by the association of this allele with these sub-phenotypes. Our results provide strong evidence for a multilevel risk model for HLA-DRB1*0301 in SLE, where the association with anti-Ro and anti-La antibody-positive SLE is much stronger than SLE without these autoantibodies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Autoanticorpos / Cadeias HLA-DRB1 / Lúpus Eritematoso Sistêmico / Modelos Genéticos Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Genes Immun Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Autoanticorpos / Cadeias HLA-DRB1 / Lúpus Eritematoso Sistêmico / Modelos Genéticos Tipo de estudo: Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Female / Humans / Male País/Região como assunto: Europa Idioma: En Revista: Genes Immun Ano de publicação: 2014 Tipo de documento: Article